Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinpi Jiegu Pian is a traditional Chinese medicine (TCM) developed and manufactured by Beijing Yushengtang Pharmaceutical Co., Ltd. It is an orally administered tablet formulated from a complex blend of herbal ingredients, including Cortex Fraxini (Qinpi), Radix Dipsaci (Xuduan), and Radix et Rhizoma Notoginseng (Sanqi). The preparation is primarily indicated for the treatment of bone fractures and traumatic injuries (跌打损伤). Mechanistically, it follows TCM principles of promoting blood circulation to resolve stasis (活血化瘀), facilitating the connection of bones and tendons (续筋接骨), and reducing swelling and pain (消肿止痛). It is an approved pharmaceutical product in China, registered under the NMPA approval number Z20025087.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qinpi jiegu pian.